Difference between revisions of "Template:Article of the week"
From LIMSWiki
Jump to navigationJump to searchShawndouglas (talk | contribs) (Updated article of the week text) |
Shawndouglas (talk | contribs) (Updated article of the week text) |
||
Line 1: | Line 1: | ||
<div style="float: left; margin: 0.5em 0.9em 0.4em 0em;">[[File: | <div style="float: left; margin: 0.5em 0.9em 0.4em 0em;">[[File:Tab1 Konnick PractLabMed2020 21.png|240px]]</div> | ||
'''"[[Journal: | '''"[[Journal:The regulatory landscape of precision oncology laboratory medicine in the United States: Perspective on the past five years and considerations for future regulation|The regulatory landscape of precision oncology laboratory medicine in the United States: Perspective on the past five years and considerations for future regulation]]"''' | ||
The | The [[Regulatory compliance|regulatory]] landscape for precision [[oncology]] in the United States is complicated, with multiple governmental regulatory agencies with different scopes of jurisdiction. Several regulatory proposals have been introduced since the [[Food and Drug Administration]] released draft guidance to regulate [[laboratory developed test]]s in 2014. Key aspects of the most recent proposals and discussion of central arguments related to the regulation of precision oncology laboratory tests provides insight to stakeholders for future discussions related to regulation of [[laboratory]] [[Medical test|tests]]. ('''[[Journal:The regulatory landscape of precision oncology laboratory medicine in the United States: Perspective on the past five years and considerations for future regulation|Full article...]]''')<br /> | ||
<br /> | <br /> | ||
''Recently featured'': | ''Recently featured'': | ||
: ▪ [[Journal:Institutional ELN-LIMS deployment: Highly customizable ELN-LIMS platform as a cornerstone of digital transformation for life sciences research institutes|Institutional ELN-LIMS deployment: Highly customizable ELN-LIMS platform as a cornerstone of digital transformation for life sciences research institutes]] | |||
: ▪ [[Journal:Health care and cybersecurity: Bibliometric analysis of the literature|Health care and cybersecurity: Bibliometric analysis of the literature]] | : ▪ [[Journal:Health care and cybersecurity: Bibliometric analysis of the literature|Health care and cybersecurity: Bibliometric analysis of the literature]] | ||
: ▪ [[Journal:Epidemiological data challenges: Planning for a more robust future through data standards|Epidemiological data challenges: Planning for a more robust future through data standards]] | : ▪ [[Journal:Epidemiological data challenges: Planning for a more robust future through data standards|Epidemiological data challenges: Planning for a more robust future through data standards]] | ||
Revision as of 16:02, 14 July 2021
The regulatory landscape for precision oncology in the United States is complicated, with multiple governmental regulatory agencies with different scopes of jurisdiction. Several regulatory proposals have been introduced since the Food and Drug Administration released draft guidance to regulate laboratory developed tests in 2014. Key aspects of the most recent proposals and discussion of central arguments related to the regulation of precision oncology laboratory tests provides insight to stakeholders for future discussions related to regulation of laboratory tests. (Full article...)
Recently featured:
- ▪ Institutional ELN-LIMS deployment: Highly customizable ELN-LIMS platform as a cornerstone of digital transformation for life sciences research institutes
- ▪ Health care and cybersecurity: Bibliometric analysis of the literature
- ▪ Epidemiological data challenges: Planning for a more robust future through data standards